PGPiet Geusens

Piet Geusens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Piet Geusens has a total of 359 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Radiographic progression in psoriatic arthritis: head-to-head comparison of the Ratingen score and the Sharp–van der Heijde method

    by Myroslava Kulyk, Silvia Scriffignano, Serge Steinfeld, Adrien Nzeusseu Toukap, Filip van Den Bosch, Rik Joos, Piet Geusens, Rik Lories, Kurt De Vlam, Marthe Van Den Berghe, et al.

    Objectives: To compare the psychometric properties (inter-rater reliability, agreement, responsiveness, and measurement error) of the Psoriatic Arthritis Ratingen Score (PARS) and modified Sharp-van der Heijde (SVDH) methods using the Belgian Psoriatic Arthritis (BePas) cohort. Methods: Radiographs of hands and feet (baseline T0, follow-ups T1, T2) were independently scored by two blinded readers using SVDH (max 528) and PARS (max 360). Statistical analyses included Intraclass Correlation Coefficient (ICC), Bland-Altman analysis, Standardized Response Mean (SRM), and Smallest Detectable Change (SDC). Results: Both methods detected positive mean change, primarily between T0 and T1. Inter-rater reliability for absolute scores was high for both (ICC >0.865; baseline ICC: PARS 0.906, SVDH 0.888). For cumulative change scores (ΔT2–T0), inter-rater reliability was low and very similar for both methods (ICC=0.483 for SVDH and 0.485 for PARS). Both methods showed moderate responsiveness over the cumulative interval (two-reader average SRM: PARS 0.571, SVDH 0.531). For both methods and both readers, mean cumulative change scores were smaller than the corresponding SDC values (PARS: 2.8–3.7% of maximum score; SVDH: 2.8–4.1%), indicating that average progression fell below the threshold of reliable individual-level detection. Bland-Altman analysis showed slightly narrower absolute limits of agreement for PARS in selected comparisons, whereas SVDH showed narrower relative limits after normalization to the maximum possible score. Conclusions: SVDH and PARS showed broadly comparable psychometric performance for PsA damage assessment. Both methods were robust for cross-sectional scoring but showed important limitations in reliably detecting cumulative change in this low-progression cohort. Neither method demonstrated clear superiority.

  • Open Access

    Family-based whole-exome sequencing implicates a variant in lysyl oxidase like 4 in atypical femur fractures

    by Wei Zhou, Denise M van de Laarschot, Jeroen G J van Rooij, Marijke Koedam, Hanh H Nguyen, André G Uitterlinden, Peter R Ebeling, Rajesh V Thakker, Piet Geusens, Bram C J van der Eerden, et al.

    Atypical femur fractures (AFFs) are rare adverse events associated with bisphosphonate use, having unclear pathophysiology. AFFs also cluster in families and have occurred in patients with monogenetic bone diseases sometimes without bisphosphonate use, suggesting an underlying genetic susceptibility. Our aim was to identify a genetic cause for AFF in a Caucasian family with 7 members affected by osteoporosis, including 3 siblings with bisphosphonate-associated AFFs. Using whole-exome sequencing, we identified a rare pathogenic variant c.G1063A (p.Gly355Ser) in lysyl oxidase like 4 (LOXL4) among 64 heterozygous rare, protein-altering variants shared by the 3 siblings with AFFs. The same variant was also found in a fourth sibling with a low-trauma femur fracture above the knee, not fulfilling all the ASBMR criteria of AFF and in 1 of 73 unrelated European AFF patients. LOXL4 is involved in collagen cross-linking and may be relevant for microcrack formation and bone repair mechanisms. Preliminary functional analysis showed that skin fibroblast-derived osteoblasts from the unrelated patient with the LOXL4 variant expressed less collagen type I and elastin, while osteogenic differentiation and mineralization were enhanced compared with 2 controls. In conclusion, this LOXL4 variant may underlie AFF susceptibility possibly due to abnormal collagen metabolism, leading to increased formation of microdamage or compromised healing of microcracks in the femur. Atypical femur fractures (AFFs) are rare fractures of the upper leg that can occur in people using bisphosphonates for osteoporosis. Genetic factors may play a role. We studied a family with 7 members affected by osteoporosis, including 3 siblings who developed AFFs after using bisphosphonates. In this family, a rare variant in the LOXL4 gene was identified as a potential cause for AFFs. This variant was also present in another sibling who had a different type of upper leg fracture, and in 1 of 73 unrelated European patients with AFFs. LOXL4 is involved in collagen cross-linking, a crucial bone formation process. The variant may impair collagen metabolism, leading to increased microdamage or compromised bone healing, which could increase the risk of AFFs.


  • The Fracture Phenotypes in Women and Men of 50 Years and Older with a Recent Clinical Fracture

    by P. Geusens, J. van Den Bergh, C. Roux, R. Chapurlat, J. Center, D. Bliuc, C. Wyers, M. K. Javaid, N. Li, D. Whittier, et al.

    Purpose of Review We review the literature about patients 50 years and older with a recent clinical fracture for the presence of skeletal and extra-skeletal risks, their perspectives of imminent subsequent fracture, falls, mortality, and other risks, and on the role of the fracture liaison service (FLS) for timely secondary fracture prevention. Recent Findings Patients with a recent clinical fracture present with heterogeneous patterns of bone-, fall-, and comorbidity-related risks. Short-term perspectives include bone loss, increased risk of fractures, falls, and mortality, and a decrease in physical performance and quality of life. Combined evaluation of bone, fall risk, and the presence of associated comorbidities contributes to treatment strategies. Summary Since fractures are related to interactions of bone-, fall-, and comorbidity-related risks, there is no one-single-discipline-fits-all approach but a need for a multidisciplinary approach at the FLS to consider all phenotypes for evaluation and treatment in an individual patient.


  • Open Access

    Bone microarchitecture and strength assessed by HRpQCT in individuals with type 2 diabetes and prediabetes: the Maastricht study

    by Veerle Van Hulten, Cindy Sarodnik, Johanna H M Driessen, Rikke Viggers, Nicklas H Rasmussen, Piet P M M Geusens, Nicolaas Schaper, Miranda T Schram, Bastiaan E De Galan, Annemarie Koster, et al.

    Type 2 diabetes (T2D) is a prevalent disease and has been associated with an increased fracture risk despite normal or even higher areal BMD. The aim of this study was to estimate the association between glucose metabolism status (GMS) and measurements of glycemic control with HRpQCT parameters of bone microarchitecture and strength. Participants of the Maastricht study who underwent an HRpQCT scan at the distal radius and tibia were included. GMS was determined by use of an oral glucose tolerance test and grouped into a normal glucose metabolism (NGM), prediabetes, or T2D. Linear regression models were used, stratified by sex with multiple adjustments. This study incorporated cross-sectional data from 1400 (796 [56.9%] NGM, 228 [16.3%] prediabetes, and 376 [26.9%] T2D) men and 1415 (1014 [71.7%] NGM, 211 [14.9%] prediabetes, and 190 [13.4%] T2D) women. The mean age was 59.8 ± 8.6 and 57.6 ± 9.0 yr for men and women, respectively. After adjustment, T2D was associated with a higher total BMD measured by HRpQCT and cortical thickness, and a smaller total and trabecular area in men and women compared with NGM. In women, T2D was additionally associated with a higher stiffness and failure load at the radius. Results were more pronounced at the distal radius than at the distal tibia. To conclude, these findings suggest that in this cohort of Maastricht study participants, total and trabecular bone area are smaller, but bone microarchitecture, density, and bone strength assessed by HRpQCT are not impaired in individuals with T2D.


  • Open Access

    High Frequency of Foot Insufficiency Fractures in Patients With Rheumatic Diseases Referred for Magnetic Resonance Imaging: What Is the Clinical Relevance?

    by Willem F. Lems, Hennie G. Raterman, Piet P.M. Geusens

    We greatly appreciated the manuscript by Björn Buehring et al1 about the high prevalence of foot insufficiency fractures (IFs) in patients with inflammatory rheumatic and musculoskeletal diseases (RMDs) who were referred for magnetic resonance imaging (MRI) because of foot pain, for several reasons. First, in using MRI, IFs were frequently diagnosed (7.5%) in referred patients with RMDs who had foot pain, and even more frequently in patients with inflammatory RMDs than in patients with noninflammatory RMDs (9.1% vs 4.1%, respectively).


  • Open Access

    Romosozumab for the treatment of postmenopausal women at high risk of fracture

    by Piet Geusens, Natasha Appelman-Dijkstra, Willem Lems, Joop van Den Bergh

    Romosozumab is a monoclonal antibody that binds to sclerostin (an inhibitor of the Wingless-related integration site (Wnt) signaling pathway). It is a new osteoanabolic drug, that simultaneously in...


  • Open Access

    How to implement guidelines and models of care

    by Piet Geusens, Natasha M. Appelman-Dijkstra, M. Carola Zillikens, Hanna Willems, Willem F. Lems, Joop van Den Bergh


  • Open Access

    Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment

    by Piet Geusens, Melissa Sam Bevers, Bert van Rietbergen, Osvaldo D Messina, Eric Lespessailles, Beatriz Oliveri, Roland Chapurlat, Klaus Engelke, Arkadi Chines, Shuang Huang, et al.

    In a randomized clinical trial in patients initiating glucocorticoid therapy (GC-I) or on long-term therapy (GC-C), denosumab every 6 months increased spine and hip bone mineral density at 12 and 24 months significantly more than daily risedronate. The aim of this study was to evaluate the effects of denosumab compared with risedronate on bone strength and microarchitecture measured by high-resolution peripheral quantitative computed tomography (HR-pQCT) in GC-I and GC-C. A subset of 110 patients had high-resolution peripheral quantitative computed tomography (HR-pQCT) scans of the distal radius and tibia at baseline and at 12 and 24 months. Cortical and trabecular microarchitecture were assessed with standard analyses and failure load (FL) with micro-finite element analysis. At the radius at 24 months, FL remained unchanged with denosumab and significantly decreased with risedronate in GC-I (−4.1%, 95% confidence interval [CI] −6.4, −1.8) and, in GC-C, it significantly increased with denosumab (4.3%, 95% CI 2.1, 6.4) and remained unchanged with risedronate. Consequently, FL was significantly higher with denosumab than with risedronate in GC-I (5.6%, 95% CI 2.4, 8.7, p < 0.001) and in GC-C (4.1%, 95% CI 1.1, 7.2, p = 0.011). We also found significant differences between denosumab and risedronate in percentage changes in cortical and trabecular microarchitectural parameters in GC-I and GC-C. Similar results were found at the tibia. To conclude, this HR-pQCT study shows that denosumab is superior to risedronate in terms of preventing FL loss at the distal radius and tibia in GC-I and in increasing FL at the radius in GC-C, based on significant differences in changes in the cortical and trabecular bone compartments between treatment groups in GC-I and GC-C. These results suggest that denosumab could be a useful therapeutic option in patients initiating GC therapy or on long-term GC therapy and may contribute to treatment decisions in this patient population. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).


  • Open Access

    Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis

    by Piet Geusens, Robert Feldman, Mary Oates, Thierry Thomas, Polyzois Makras, Franz Jakob, Bente Langdahl, Zhenxun Wang, Maria Rojeski, Cesar Libanati